Sectoral Asset Management Inc. Sells 4,536 Shares of BeOne Medicines Ltd. – Sponsored ADR $ONC

Sectoral Asset Management Inc. lowered its position in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 63.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,665 shares of the company’s stock after selling 4,536 shares during the period. Sectoral Asset Management Inc.’s holdings in BeOne Medicines were worth $810,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Leonteq Securities AG bought a new position in shares of BeOne Medicines during the fourth quarter worth approximately $35,000. Daiwa Securities Group Inc. bought a new position in shares of BeOne Medicines during the second quarter worth approximately $35,000. CWM LLC increased its stake in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares during the period. Farther Finance Advisors LLC increased its stake in shares of BeOne Medicines by 21.8% during the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after purchasing an additional 39 shares during the period. Finally, EverSource Wealth Advisors LLC bought a new position in shares of BeOne Medicines during the second quarter worth approximately $68,000. Institutional investors own 48.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Barclays increased their price target on BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Jefferies Financial Group downgraded BeOne Medicines from a “buy” rating to a “hold” rating and reduced their price target for the stock from $420.00 to $290.00 in a research report on Monday, March 16th. Leerink Partners increased their price target on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, BeOne Medicines presently has a consensus rating of “Moderate Buy” and a consensus price target of $389.15.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, SVP Chan Henry Lee sold 332 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $310.72, for a total value of $103,159.04. Following the sale, the senior vice president owned 101 shares of the company’s stock, valued at approximately $31,382.72. This trade represents a 76.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 1,005 shares of company stock valued at $308,907. Company insiders own 6.19% of the company’s stock.

BeOne Medicines Stock Performance

Shares of ONC stock opened at $310.25 on Monday. The stock’s fifty day moving average price is $300.77 and its two-hundred day moving average price is $321.47. The company has a market cap of $34.04 billion, a PE ratio of 69.41 and a beta of 0.50. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $235.35 and a fifty-two week high of $385.22. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Equities analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 EPS for the current fiscal year.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.